Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis (Q26776496)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Giampaolo Merlini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1

Morie A Gertz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Merrill D Benson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Peter J Dyck

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Martha Grogan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Terresa Coelho

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Marcia Cruz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

John L Berk

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Violaine Plante-Bordeneuve

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American College of Cardiology

8 June 2020

language of work or name

English

0 references

publication date

1 December 2015

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

2451-2466

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis.

8 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Liver transplantation in transthyretin amyloidosis: issues and challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Liver transplantation and transthyretin amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Review: history of the amyloid fibril

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Haplotype analysis of common transthyretin mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Green tea halts progression of cardiac transthyretin amyloidosis: an observational report

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Amyloid in endomyocardial biopsies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Natural history and therapy of AL cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Tafamidis: a review of its use in familial amyloid polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Amyloidosis and endomyocardial biopsy: Correlation of extent and pattern of deposition with amyloid immunophenotype in 100 cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Characterization of Cardiac Amyloidosis by Atrial Late Gadolinium Enhancement Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging and Correlation With Left Atrial Conduit and Contractile Function

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Selective silencing of a mutant transthyretin allele by small interfering RNAs

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Proportion between wild-type and mutant protein in truncated compared to full-length ATTR: an analysis on transplanted transthyretin T60A amyloidosis patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Left ventricular device implantation for advanced cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Prophylactic pacemaker implantation in familial amyloid polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: a proteomic approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Transthyretin V122I in African Americans with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Infiltrative cardiovascular diseases: cardiomyopathies that look alike

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Native T1 mapping in transthyretin amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Noninvasive risk stratification of patients with transthyretin amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Identification of TTR-Related Subclinical Amyloidosis With 99mTc-DPD Scintigraphy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Right ventricular dilation in primary amyloidosis: an independent predictor of survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

The premortem recognition of systemic senile amyloidosis with cardiac involvement.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Pathophysiology and treatment of cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

A look into amyloid formation by transthyretin: aggregation pathway and a novel kinetic model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

The amyloidogenic V122I transthyretin variant in elderly black Americans

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

4 ′‐iodo‐4′‐Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Prevalence of germline mutations in the TTR gene in a consecutive series of surgical pathology specimens with ATTR amyloid.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the spanish registry for heart transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Diflunisal for ATTR cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Implantable cardioverter defibrillators in patients with cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

RNAi therapies: drugging the undruggable

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Changes in pathological and biochemical findings of systemic tissue sites in familial amyloid polyneuropathy more than 10 years after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Minimally invasive minor salivary gland biopsy for the diagnosis of amyloidosis in a rheumatology clinic

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Digoxin sensitivity in amyloid cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

A practical approach to the diagnosis of systemic amyloidoses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Progression of transthyretin amyloid neuropathy after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Transthyretin: a multifaceted protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Comparison between (99m)Tc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Regional differences and similarities of FAP in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Senile systemic amyloidosis: are regional differences real or do they reflect different diagnostic suspicion and use of techniques?

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Arterial thromboembolism in senile systemic amyloidosis: report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Regional difference and similarity of familial amyloidosis with polyneuropathy in France

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

The prognostic significance of central hemodynamics in patients with cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Usefulness of plasma B-type natriuretic peptide as a prognostic marker of cardiac function in senile systemic amyloidosis and in familial amyloidotic polyneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Bone scintigraphy with99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Hereditary ATTR amyloidosis: a single-institution experience with 266 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

Cardiac amyloidosis. Two cases with digitalis sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.JACC.2015.09.075

7 January 2021

10.1016/J.JACC.2015.09.075

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

2230436

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json

release_ndllqcttz5amzckotoycatdz3m

8 June 2020

Fatcat ID

0 references

2230436

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

2230436

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26610878%20AND%20SRC:MED&resulttype=core&format=json